Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Resverlogix Corp (RVX.TO)

Resverlogix Corp (RVX.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 16,330
  • Shares Outstanding, K 272,171
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,610 K
  • 60-Month Beta 1.43
  • Price/Sales N/A
  • Price/Cash Flow 14.98
  • Price/Book N/A
Trade RVX.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.04
  • Most Recent Earnings $-0.02 on N/A
  • Latest Earnings Date 03/29/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0550 +9.09%
on 03/04/24
0.0650 -7.69%
on 03/12/24
-0.0050 (-7.69%)
since 02/16/24
3-Month
0.0550 +9.09%
on 03/04/24
0.0750 -20.00%
on 12/28/23
unch (unch)
since 12/18/23
52-Week
0.0550 +9.09%
on 03/04/24
0.2600 -76.92%
on 04/04/23
-0.1000 (-62.50%)
since 03/17/23

Most Recent Stories

More News
Resverlogix Announces Change to Its Board of Directors

Calgary, Alberta--(Newsfile Corp. - February 21, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announced that Shawn Lu has stepped down from the Board of Directors, effective...

RVXCF : 0.0480 (unch)
RVX.TO : 0.0600 (unch)
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits

Calgary, Alberta--(Newsfile Corp. - January 11, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", "the Company") today announced publication of an article, entitled, "The BET inhibitor apabetalone decreases...

RVXCF : 0.0480 (unch)
RVX.TO : 0.0600 (unch)
Stocks in play: Resverlogix Corp.

Today announced the publication of a peer-reviewed article, entitled "Apabetalone, a Clinical-stage, ...

RVX.TO : 0.0600 (unch)
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

Calgary, Alberta--(Newsfile Corp. - October 4, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced the publication of a peer-reviewed article, entitled "Apabetalone, a Clinical-stage,...

RVXCF : 0.0480 (unch)
RVX.TO : 0.0600 (unch)
Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes

Amsterdam, Netherlands and Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") (TSX:RVX) today announced that new guidelines published by the European Society...

RVXCF : 0.0480 (unch)
RVX.TO : 0.0600 (unch)
Resverlogix Announces Warrant Repricing and One-Year Extension

Calgary, Alberta--(Newsfile Corp. - June 29, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announces that certain of its 27,461,157 common share purchase warrants (the "Warrants")...

RVX.TO : 0.0600 (unch)
RVXCF : 0.0480 (unch)
Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders

Calgary, Alberta--(Newsfile Corp. - June 20, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta.During...

RVX.TO : 0.0600 (unch)
RVXCF : 0.0480 (unch)
Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients

Calgary, Alberta--(Newsfile Corp. - June 12, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced a peer-reviewed article, entitled, "Apabetalone Downregulates Fibrotic, Inflammatory and...

RVX.TO : 0.0600 (unch)
RVXCF : 0.0480 (unch)
Resverlogix Announces One-Year Extension of Debenture

Calgary, Alberta--(Newsfile Corp. - March 20, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that it has closed a one-year extension of Company's US$6.0 million secured...

RVX.TO : 0.0600 (unch)
RVXCF : 0.0480 (unch)
Resverlogix Announces New Research Highlighting Apabetalone's Potential Benefits in Cardiovascular Disease, Heart Failure, and COVID-19

Calgary, Alberta--(Newsfile Corp. - March 2, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced the publication of two articles in peer-reviewed scientific journals. The first, entitled...

RVX.TO : 0.0600 (unch)
RVXCF : 0.0480 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.0600
2nd Resistance Point 0.0600
1st Resistance Point 0.0600
Last Price 0.0600
1st Support Level 0.0600
2nd Support Level 0.0600
3rd Support Level 0.0600

See More

52-Week High 0.2600
Fibonacci 61.8% 0.1817
Fibonacci 50% 0.1575
Fibonacci 38.2% 0.1333
Last Price 0.0600
52-Week Low 0.0550

See More

Business Summary

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar